Colchicine treatment can improve outcomes of coronavirus disease 2019 (COVID‐19): A systematic review and meta‐analysis

• Published in: Clinical and experimental pharmacology & physiology Vol. 48; no. 6; pp. 823 - 830
• Main Authors: Hariyanto, Timotius Ivan, Halim, Devina Adella, Jodhinata, Claudia, Yanto, Theo Audi, Kurniawan, Andree
• Format: Journal Article
• Language: English
• Published: Australia Wiley Subscription Services, Inc 01.06.2021; John Wiley and Sons Inc
• Subjects: Clinical trials; Colchicine; Colchicine - pharmacology; Colchicine - therapeutic use; Coronaviridae; coronavirus disease 2019; Coronaviruses; COVID-19; COVID-19 - diagnosis; COVID-19 - mortality; COVID-19 Drug Treatment; Health services; Humans; immune therapy; Inflammation; Inflammatory diseases; Meta-analysis; Modelling; Mortality - trends; Observational studies; Patients; Randomized Controlled Trials as Topic - methods; Rapid Communication; Reduction; SARS-CoV-2 - drug effects; Statistical analysis; Subgroups; treatment; Treatment Outcome; Tubulin Modulators - pharmacology; Tubulin Modulators - therapeutic use; Viral diseases; treatment; colchicine; immune therapy; coronavirus disease 2019

Currently, there is no widely acceptable and proven effective treatment for coronavirus disease 2019 (COVID‐19). Colchicine has been shown to offer a benefit in reducing the inflammation in several inflammatory diseases. This study aims to analyze the efficacy of colchicine administration and outcom...